These findings underscore the potential impact of ABC transporter gene alterations on patient prognosis, particularly in prostate cancer, and highlight the need for further investigation into their role in cancer progression and therapeutic resistance. The gene discussed is ABCG2; the disease is Familial prostate cancer.